Ireland - English - HPRA (Health Products Regulatory Authority)

lexon (uk) ltd - lamotrigine - chewable/dispersible tablet - 200 milligram(s) - other antiepileptics; lamotrigine

Ireland - English - HPRA (Health Products Regulatory Authority)

lexon (uk) ltd - lamotrigine - chewable/dispersible tablet - 50 milligram(s) - other antiepileptics; lamotrigine

Ireland - English - HPRA (Health Products Regulatory Authority)

lexon (uk) ltd - lamotrigine - chewable/dispersible tablet - 100 milligram(s) - other antiepileptics; lamotrigine

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

glaxosmithkline uk ltd - lamotrigine - dispersible tablet - 5mg

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

glaxosmithkline uk ltd - lamotrigine - dispersible tablet - 25mg

Australia - English - Department of Health (Therapeutic Goods Administration)

aspen pharmacare australia pty ltd - lamotrigine, quantity: 50 mg - tablet, uncoated - excipient ingredients: povidone; microcrystalline cellulose; iron oxide yellow; magnesium stearate; lactose monohydrate; sodium starch glycollate - lamictal is an anti-epileptic drug for the treatment of partial and generalised seizures in adults and children. there is extensive experience with lamictal used initially as ?add-on? therapy. the use of lamictal has also been found to be effective as monotherapy following withdrawal of concomitant anti-epileptic drugs. initial monotherapy treatment in newly diagnosed paediatric patients is not recommended (see clinical trials). lamictal is indicated for the prevention of depressive episodes in patients with bipolar disorder.

Australia - English - Department of Health (Therapeutic Goods Administration)

aspen pharmacare australia pty ltd - lamotrigine, quantity: 100 mg - tablet, uncoated - excipient ingredients: lactose monohydrate; iron oxide yellow; povidone; magnesium stearate; sodium starch glycollate; microcrystalline cellulose - lamictal is an anti-epileptic drug for the treatment of partial and generalised seizures in adults and children. there is extensive experience with lamictal used initially as ?add-on? therapy. the use of lamictal has also been found to be effective as monotherapy following withdrawal of concomitant anti-epileptic drugs. initial monotherapy treatment in newly diagnosed paediatric patients is not recommended (see clinical trials). lamictal is indicated for the prevention of depressive episodes in patients with bipolar disorder.

Australia - English - Department of Health (Therapeutic Goods Administration)

aspen pharmacare australia pty ltd - lamotrigine, quantity: 200 mg - tablet, uncoated - excipient ingredients: magnesium stearate; povidone; sodium starch glycollate; microcrystalline cellulose; iron oxide yellow; lactose monohydrate - lamictal is an anti-epileptic drug for the treatment of partial and generalised seizures in adults and children. there is extensive experience with lamictal used initially as add-on therapy. the use of lamictal has also been found to be effective as monotherapy following withdrawal of concomitant anti-epileptic drugs. initial monotherapy treatment in newly diagnosed paediatric patients is not recommended (see clinical trials). lamictal is indicated for the prevention of depressive episodes in patients with bipolar disorder.

Ireland - English - HPRA (Health Products Regulatory Authority)

lexon pharmaceuticals (ireland) limited - lamotrigine - chewable/dispersible tablet - 100 milligram(s) - other antiepileptics; lamotrigine

Ireland - English - HPRA (Health Products Regulatory Authority)

lexon pharmaceuticals (ireland) limited - lamotrigine - chewable/dispersible tablet - 200 milligram(s) - other antiepileptics; lamotrigine